Zymeworks Inc. (ZYME): who owns it and who trades it
As of Nov 16, 2026, ZYME insiders reported 14 open-market sales worth $6.1M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kenneth Galbraith (CEO), with $3.3M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Zymeworks
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ZYME
204 funds and institutions reported ZYME shares worth $1.9B at the end of Q2 2026, about 96% of the company. The largest holder is EcoR1 Capital, LLC with 31.1%.
Funds and institutions (13F) 96%Everyone else 4%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 22.97M | 31.15% | $600M | No change |
| Rubric Capital Management LP | 7.00M | 9.49% | $183M | No change |
| BlackRock, Inc. | 4.25M | 5.76% | $111M | -7% |
| Perceptive Advisors LLC | 4.18M | 5.67% | $109M | +19% |
| Bvf Inc | 3.65M | 4.95% | $95.4M | -2% |
| Assenagon Asset Management S.A. | 2.50M | 3.40% | $65.5M | +244% |
| Morgan Stanley | 2.23M | 3.03% | $58.3M | -10% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.78M | 2.42% | $46.6M | -7% |
| Vanguard Capital Management LLC | 1.56M | 2.11% | $40.8M | -9% |
| Nextech Invest Ltd. | 1.11M | 1.51% | $29.1M | No change |
| State Street Corp | 1.09M | 1.48% | $28.4M | +8% |
| Dimensional Fund Advisors LP | 994,955 | 1.35% | $26M | -13% |
| California State Teachers Retirement System | 986,628 | 1.34% | $37.7M | +2539% |
| Citadel Advisors LLC | 914,136 | 1.24% | $23.9M | -21% |
| Nomura Asset Management International Inc. | 889,802 | 1.21% | $23.3M | – |
| FMR LLC (Fidelity) | 702,568 | 0.95% | $18.4M | +5% |
| Geode Capital Management, LLC | 692,410 | 0.94% | $18.1M | +5% |
| Prosight Management, LP | 674,434 | 0.91% | $17.6M | +25% |
| Qube Research & Technologies Ltd | 593,590 | 0.80% | $15.5M | +16% |
| Vanguard Portfolio Management LLC | 510,032 | 0.69% | $13.3M | +2% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ZYME insiders reported $0 of open-market purchases and $6.1M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Paul Andrew Moore | Chief Scientific Officer | Sale | 7,367 | $26.14 | $193K | Form 4 |
| Nov 13, 2026 | Paul Andrew Moore | Chief Scientific Officer | Sale | 7,374 | $26.09 | $192K | Form 4 |
| Nov 13, 2026 | Paul Andrew Moore | Chief Scientific Officer | Sale | 25,000 | $26.04 | $651K | Form 4 |
| Oct 9, 2026 | Adam Schayowitz | Vice president | Sale | 13,832 | $25.85 | $358K | Form 4 |
| Jan 12, 2026 | Mark Hollywood | Vice president | Sale | 6,120 | $22.67 | $139K | Form 4 |
| Jan 12, 2026 | Jeffrey T L Smith | Vice president | Sale | 9,310 | $22.67 | $211K | Form 4 |
| Jan 12, 2026 | Paul Andrew Moore | Chief Scientific Officer | Sale | 9,560 | $22.67 | $217K | Form 4 |
| Jan 12, 2026 | Kenneth Galbraith | CEO | Sale | 30,424 | $22.67 | $690K | Form 4 |
| Jan 5, 2026 | Jeffrey T L Smith | Vice president | Sale | 10,538 | $25.10 | $265K | Form 4 |
| Jan 5, 2026 | Kenneth Galbraith | CEO | Sale | 31,686 | $25.10 | $795K | Form 4 |
| Jan 5, 2026 | Kenneth Galbraith | CEO | Sale | 22,657 | $25.10 | $569K | Form 4 |
| Jan 5, 2026 | Paul Andrew Moore | Chief Scientific Officer | Sale | 10,821 | $25.10 | $272K | Form 4 |
| Jan 5, 2026 | Paul Andrew Moore | Chief Scientific Officer | Sale | 9,289 | $25.10 | $233K | Form 4 |
| Dec 22, 2025 | Kenneth Galbraith | CEO | Sale | 47,528 | $27.02 | $1.3M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kenneth Galbraith | Chair & CEO, Director | – | $3.3M | Jan 12, 2026 |
| Paul Andrew Moore | Chief Scientific Officer | – | $1.8M | Nov 13, 2026 |
| Jeffrey T L Smith | EVP & Chief Medical Officer | – | $476K | Jan 12, 2026 |
| Adam Schayowitz | EVP, Head of R&D | – | $358K | Oct 9, 2026 |
| Mark Hollywood | EVP & Chief Operating Officer | – | $139K | Jan 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ZYME short interest
Moderate short interest. 8.3% of ZYME shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went up 32%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.91M ZYME shares were sold short, 8.3% of the shares outstanding, up 6.0% from the report before. At the average daily volume of 1.39M shares, buying them all back would take about 4.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.91M | 8.34% | +6% | 1.39M | 4.2 |
| Oct 15, 2026 | 5.58M | 7.86% | +5% | 1.28M | 4.4 |
| Sep 30, 2026 | 5.29M | 7.46% | +7% | 953,928 | 5.5 |
| Sep 15, 2026 | 4.94M | 6.96% | +5% | 619,914 | 8.0 |
| Aug 31, 2026 | 4.72M | 6.66% | +4% | 827,575 | 5.7 |
| Aug 14, 2026 | 4.54M | 6.40% | +11% | 533,925 | 8.5 |
| Jul 31, 2026 | 4.11M | 5.57% | +0% | 376,796 | 10.9 |
| Jul 15, 2026 | 4.10M | 5.56% | -6% | 542,279 | 7.6 |
| Jun 30, 2026 | 4.36M | 5.92% | -3% | 704,780 | 6.2 |
| Jun 15, 2026 | 4.49M | 6.08% | -1% | 804,667 | 5.6 |
| May 29, 2026 | 4.53M | 6.14% | +1% | 594,680 | 7.6 |
| May 15, 2026 | 4.47M | 6.06% | -4% | 673,335 | 6.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Zymeworks company events
Zymeworks filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 23, 2026AgreementZymeworks Inc. and its subsidiary Zymeworks BC Inc. (together, the “Company”) entered into a Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”), granting Roche exclusive rights to develop and commercialize the Company’s proprietary… Filing
- Sep 23, 2026DealThe information set forth in the Introductory Note and Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
- Aug 25, 2026AnnouncementREGULATION FD DISCLOSURES Zymeworks BC Inc., a subsidiary of the Company, is a party to an Amended and Restated License and Collaboration Agreement (as amended, the “License and Collaboration Agreement”) with Jazz Pharmaceuticals Ireland Limited, a subsidiary of Jazz Pharmaceuticals plc… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 29, 2026AgreementZymeworks Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Zymeworks Merger Sub 1, an exempted company with limited liability incorporated under the Laws of the Cayman Islands and a wholly owned subsidiary of Parent, and Theravance Biopharma, Inc., an exempted company… Filing
- May 14, 2026AnnouncementZymeworks Inc. issued a press release announcing that its Board of Directors had authorized a share repurchase program under which the Company may repurchase up to $125.0 million of the Company’s common stock, par value $0.00001 per share. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 1, 2026LeadershipZymeworks Inc. appointed Ms. Kristin Stafford, age 44, as Executive Vice President, Chief Financial Officer of the Company, effective upon her commencement of employment with the Company on April 1, 2026. Filing
- Mar 2, 2026AgreementZymeworks BC Inc., a subsidiary of Zymeworks Inc., entered into a sale agreement with Zymeworks Royalty Limited Partnership, a special purpose entity newly formed by Zymeworks BC and by its general partner Zymeworks General Partner ULC, the Company solely for the purpose of certain indemnification… Filing
- Mar 2, 2026ResultsReleased financial results. Filing
- Jan 12, 2026LeadershipThe board of directors of the Company, upon recommendation from the nominating and corporate governance committee of the Board appointed Mr. Brian Cherry as a Class II director of the Company effective January 12, 2026, with a term expiring at the Company’s 2026 annual general meeting of… Filing
- Dec 30, 2025VoteReported shareholder vote results. Filing
- Nov 18, 2025LeadershipMr. Scott Platshon submitted his resignation from the board of directors of Zymeworks Inc., effective immediately. Filing
- Nov 17, 2025AnnouncementZymeworks Inc. issued a press release announcing positive topline results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera ® (zanidatamab-hrii) in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra ® (tislelizumab), as a first-line treatment for HER2-positive (HER2+)… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Zymeworks financials
Famous investors that hold ZYME
5 of the 50 well-known investors we track reported holding ZYME in their latest 13F filing. The largest position is Ken Griffin's, worth $31.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.19M | $31.6M | 0.0% | +30% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 608,612 | $16.1M | 0.0% | +760% |
| Israel Englander · Millennium Management | Q3 2026 | 400,074 | $10.6M | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 75,369 | $2M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 26,800 | $710K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Zymeworks Inc. (ZYME) stock
Who owns the most ZYME stock?
The largest reported owner of Zymeworks Inc. (ZYME) is EcoR1 Capital, LLC, with 31.1% of the company. In total, 204 funds and institutions reported holding ZYME at the end of Q2 2026, together about 96% of the shares. See the largest owners.
Are ZYME insiders buying or selling?
In the last 12 months, ZYME insiders reported no open-market purchases and 14 sales worth $6.1M. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in ZYME?
As of Oct 30, 2026, 5.91M ZYME shares were sold short, 8.3% of the shares outstanding, up 6.0% from the report before. At the average daily volume of 1.39M shares, buying them all back would take about 4.2 trading days (days to cover). See the history.
Which famous investors hold ZYME?
5 of the 50 well-known investors we track reported ZYME in their latest 13F filing, including Ken Griffin, Ken Fisher, Israel Englander. The largest position is worth $31.6M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.